Zeta IDH1 (R132H) Antibody. Zeta’s recombinant rabbit antibody recognizes IDH1 (R132H) but specifically binds to the IDH1-mutated protein but does not bind the wild-type IDH1 protein. IDH1 (R132H) point mutations are frequently seen in grade II and III gliomas, and the IDH1 (R132H) point mutations are believed to constitute an early step in tumorigenesis. IDH1 (R132H) can be used as a diagnostic marker to help differentiate infiltrating gliomas from gliosis and as a prognostic marker for gliomas and secondary glioblastoma multiforme. IDH1 (R132H) antibody shows strong cytoplasmic staining and weaker nuclear staining in tumor cells with the IDH1 (R132H)-mutated peptide. The IDH1 antibody shows diffuse staining of the fibrillary tumor matrix
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.